APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dasatinib Generics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dasatinib Generics Market Outlook and Growth Opportunities 2026

27 December 2025194 pages

Choose your research edition.

Industry ResearchDasatinib Generics Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Dasatinib Generics Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Dasatinib Generics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dasatinib Generics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Dasatinib Generics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Dasatinib Generics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dasatinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dasatinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dasatinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dasatinib Generics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dasatinib Generics market include Bristol Myers Squibb, Lupin, Sawai Pharmaceutical, XSpray Pharma, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical and Chia Tai Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dasatinib Generics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dasatinib Generics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dasatinib Generics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dasatinib Generics market size, projected growth trends, production technologies, key applications, and end-use industries.

Dasatinib Generics Segment by Company

Bristol Myers Squibb

Lupin

Sawai Pharmaceutical

XSpray Pharma

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Dasatinib Generics Segment by Type

80mg per Tablet

70mg per Tablet

50mg per Tablet

20mg per Tablet

140mg per Tablet

100mg per Tablet

Dasatinib Generics Segment by Application

Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia

Dasatinib Generics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dasatinib Generics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dasatinib Generics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dasatinib Generics significant trends, drivers, influence factors in global and regions.

6. To analyze Dasatinib Generics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dasatinib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dasatinib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dasatinib Generics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dasatinib Generics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dasatinib Generics industry.

Chapter 3: Detailed analysis of Dasatinib Generics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dasatinib Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dasatinib Generics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dasatinib Generics Industry Trends Table 2. Dasatinib Generics Industry Drivers Table 3. Dasatinib Generics Industry Opportunities and Challenges Table 4. Dasatinib Generics Industry Restraints Table 5. Global Dasatinib Generics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dasatinib Generics Revenue Share by Company (2021-2026) Table 7. Global Dasatinib Generics Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dasatinib Generics Sales Volume Share by Company (2021-2026) Table 9. Global Dasatinib Generics Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dasatinib Generics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dasatinib Generics Key Company Manufacturing Base & Headquarters Table 12. Global Dasatinib Generics Company, Product Type & Application Table 13. Global Dasatinib Generics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dasatinib Generics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 80mg per Tablet Table 18. Significant Companies of 70mg per Tablet Table 19. Significant Companies of 50mg per Tablet Table 20. Significant Companies of 20mg per Tablet Table 21. Significant Companies of 140mg per Tablet Table 22. Significant Companies of 100mg per Tablet Table 23. Global Dasatinib Generics Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Dasatinib Generics Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Dasatinib Generics Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Dasatinib Generics Sales Volume Share by Type (2021-2026) Table 27. Global Dasatinib Generics Sales Volume Share by Type (2027-2032) Table 28. Global Dasatinib Generics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Dasatinib Generics Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Dasatinib Generics Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Dasatinib Generics Sales Value Share by Type (2021-2026) Table 32. Global Dasatinib Generics Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Acute Lymphocytic Leukemia Table 34. Significant Companies of Chronic Myeloid Leukemia Table 35. Global Dasatinib Generics Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Dasatinib Generics Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Dasatinib Generics Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Dasatinib Generics Sales Volume Share by Application (2021-2026) Table 39. Global Dasatinib Generics Sales Volume Share by Application (2027-2032) Table 40. Global Dasatinib Generics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Dasatinib Generics Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Dasatinib Generics Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Dasatinib Generics Sales Value Share by Application (2021-2026) Table 44. Global Dasatinib Generics Sales Value Share by Application (2027-2032) Table 45. Global Dasatinib Generics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Dasatinib Generics Sales by Region (2021-2026) & (K Units) Table 47. Global Dasatinib Generics Sales Market Share by Region (2021-2026) Table 48. Global Dasatinib Generics Sales by Region (2027-2032) & (K Units) Table 49. Global Dasatinib Generics Sales Market Share by Region (2027-2032) Table 50. Global Dasatinib Generics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Dasatinib Generics Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Dasatinib Generics Sales Value Share by Region (2021-2026) Table 53. Global Dasatinib Generics Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Dasatinib Generics Sales Value Share by Region (2027-2032) Table 55. Global Dasatinib Generics Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Dasatinib Generics Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Dasatinib Generics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Dasatinib Generics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Dasatinib Generics Sales by Country (2021-2026) & (K Units) Table 60. Global Dasatinib Generics Sales Market Share by Country (2021-2026) Table 61. Global Dasatinib Generics Sales by Country (2027-2032) & (K Units) Table 62. Global Dasatinib Generics Sales Market Share by Country (2027-2032) Table 63. Global Dasatinib Generics Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Dasatinib Generics Sales Value Market Share by Country (2021-2026) Table 65. Global Dasatinib Generics Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Dasatinib Generics Sales Value Market Share by Country (2027-2032) Table 67. Bristol Myers Squibb Company Information Table 68. Bristol Myers Squibb Business Overview Table 69. Bristol Myers Squibb Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Bristol Myers Squibb Dasatinib Generics Product Portfolio Table 71. Bristol Myers Squibb Recent Development Table 72. Lupin Company Information Table 73. Lupin Business Overview Table 74. Lupin Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Lupin Dasatinib Generics Product Portfolio Table 76. Lupin Recent Development Table 77. Sawai Pharmaceutical Company Information Table 78. Sawai Pharmaceutical Business Overview Table 79. Sawai Pharmaceutical Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sawai Pharmaceutical Dasatinib Generics Product Portfolio Table 81. Sawai Pharmaceutical Recent Development Table 82. XSpray Pharma Company Information Table 83. XSpray Pharma Business Overview Table 84. XSpray Pharma Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. XSpray Pharma Dasatinib Generics Product Portfolio Table 86. XSpray Pharma Recent Development Table 87. Qilu Pharmaceutical Company Information Table 88. Qilu Pharmaceutical Business Overview Table 89. Qilu Pharmaceutical Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Qilu Pharmaceutical Dasatinib Generics Product Portfolio Table 91. Qilu Pharmaceutical Recent Development Table 92. CSPC Ouyi Pharmaceutical Company Information Table 93. CSPC Ouyi Pharmaceutical Business Overview Table 94. CSPC Ouyi Pharmaceutical Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. CSPC Ouyi Pharmaceutical Dasatinib Generics Product Portfolio Table 96. CSPC Ouyi Pharmaceutical Recent Development Table 97. Chia Tai Tianqing Pharmaceutical Company Information Table 98. Chia Tai Tianqing Pharmaceutical Business Overview Table 99. Chia Tai Tianqing Pharmaceutical Dasatinib Generics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Chia Tai Tianqing Pharmaceutical Dasatinib Generics Product Portfolio Table 101. Chia Tai Tianqing Pharmaceutical Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Dasatinib Generics Distributors List Table 105. Dasatinib Generics Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Dasatinib Generics Product Image Figure 2. Global Dasatinib Generics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dasatinib Generics Sales (2021-2032) & (K Units) Figure 5. Global Dasatinib Generics Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dasatinib Generics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 80mg per Tablet Image Figure 10. 70mg per Tablet Image Figure 11. 50mg per Tablet Image Figure 12. 20mg per Tablet Image Figure 13. 140mg per Tablet Image Figure 14. 100mg per Tablet Image Figure 15. Global Dasatinib Generics Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Dasatinib Generics Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Dasatinib Generics Sales Volume Share by Type (2021-2032) Figure 18. Global Dasatinib Generics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Dasatinib Generics Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Dasatinib Generics Sales Value Share by Type (2021-2032) Figure 21. Acute Lymphocytic Leukemia Image Figure 22. Chronic Myeloid Leukemia Image Figure 23. Global Dasatinib Generics Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Dasatinib Generics Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Dasatinib Generics Sales Volume Share by Application (2021-2032) Figure 26. Global Dasatinib Generics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Dasatinib Generics Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Dasatinib Generics Sales Value Share by Application (2021-2032) Figure 29. Global Dasatinib Generics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Dasatinib Generics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Dasatinib Generics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Dasatinib Generics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 34. North America Dasatinib Generics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Dasatinib Generics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Dasatinib Generics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 40. South America Dasatinib Generics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Dasatinib Generics Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Dasatinib Generics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Dasatinib Generics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Dasatinib Generics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Dasatinib Generics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Dasatinib Generics Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Dasatinib Generics Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • 80mg per Tablet
  • 70mg per Tablet
  • 50mg per Tablet
  • 20mg per Tablet
  • 140mg per Tablet
  • 100mg per Tablet
Applications
  • Acute Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
Companies covered
  • Bristol Myers Squibb
  • Lupin
  • Sawai Pharmaceutical
  • XSpray Pharma
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dasatinib Generics Sales Value (2021-2032)
  4. 1.2.2 Global Dasatinib Generics Sales Volume (2021-2032)
  5. 1.2.3 Global Dasatinib Generics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dasatinib Generics Market Dynamics
  1. 2.1 Dasatinib Generics Industry Trends
  2. 2.2 Dasatinib Generics Industry Drivers
  3. 2.3 Dasatinib Generics Industry Opportunities and Challenges
  4. 2.4 Dasatinib Generics Industry Restraints
3 Dasatinib Generics Market by Company
  1. 3.1 Global Dasatinib Generics Company Revenue Ranking in 2025
  2. 3.2 Global Dasatinib Generics Revenue by Company (2021-2026)
  3. 3.3 Global Dasatinib Generics Sales Volume by Company (2021-2026)
  4. 3.4 Global Dasatinib Generics Average Price by Company (2021-2026)
  5. 3.5 Global Dasatinib Generics Company Ranking (2024-2026)
  6. 3.6 Global Dasatinib Generics Company Manufacturing Base and Headquarters
  7. 3.7 Global Dasatinib Generics Company Product Type and Application
  8. 3.8 Global Dasatinib Generics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dasatinib Generics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dasatinib Generics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dasatinib Generics Market by Type
  1. 4.1 Dasatinib Generics Type Introduction
  2. 4.1.1 80mg per Tablet
  3. 4.1.2 70mg per Tablet
  4. 4.1.3 50mg per Tablet
  5. 4.1.4 20mg per Tablet
  6. 4.1.5 140mg per Tablet
  7. 4.1.6 100mg per Tablet
  8. 4.2 Global Dasatinib Generics Sales Volume by Type
  9. 4.2.1 Global Dasatinib Generics Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Dasatinib Generics Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Dasatinib Generics Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Dasatinib Generics Sales Value by Type
  13. 4.3.1 Global Dasatinib Generics Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Dasatinib Generics Sales Value by Type (2021-2032)
  15. 4.3.3 Global Dasatinib Generics Sales Value Share by Type (2021-2032)
5 Dasatinib Generics Market by Application
  1. 5.1 Dasatinib Generics Application Introduction
  2. 5.1.1 Acute Lymphocytic Leukemia
  3. 5.1.2 Chronic Myeloid Leukemia
  4. 5.2 Global Dasatinib Generics Sales Volume by Application
  5. 5.2.1 Global Dasatinib Generics Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Dasatinib Generics Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Dasatinib Generics Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Dasatinib Generics Sales Value by Application
  9. 5.3.1 Global Dasatinib Generics Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Dasatinib Generics Sales Value by Application (2021-2032)
  11. 5.3.3 Global Dasatinib Generics Sales Value Share by Application (2021-2032)
6 Dasatinib Generics Regional Sales and Value Analysis
  1. 6.1 Global Dasatinib Generics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dasatinib Generics Sales by Region (2021-2032)
  3. 6.2.1 Global Dasatinib Generics Sales by Region: 2021-2026
  4. 6.2.2 Global Dasatinib Generics Sales by Region (2027-2032)
  5. 6.3 Global Dasatinib Generics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dasatinib Generics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dasatinib Generics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dasatinib Generics Sales Value by Region (2027-2032)
  9. 6.5 Global Dasatinib Generics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dasatinib Generics Sales Value (2021-2032)
  12. 6.6.2 North America Dasatinib Generics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dasatinib Generics Sales Value (2021-2032)
  15. 6.7.2 Europe Dasatinib Generics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dasatinib Generics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dasatinib Generics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dasatinib Generics Sales Value (2021-2032)
  21. 6.9.2 South America Dasatinib Generics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dasatinib Generics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dasatinib Generics Sales Value Share by Country, 2025 VS 2032
7 Dasatinib Generics Country-level Sales and Value Analysis
  1. 7.1 Global Dasatinib Generics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dasatinib Generics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dasatinib Generics Sales by Country (2021-2032)
  4. 7.3.1 Global Dasatinib Generics Sales by Country (2021-2026)
  5. 7.3.2 Global Dasatinib Generics Sales by Country (2027-2032)
  6. 7.4 Global Dasatinib Generics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dasatinib Generics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dasatinib Generics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dasatinib Generics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dasatinib Generics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dasatinib Generics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dasatinib Generics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dasatinib Generics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dasatinib Generics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dasatinib Generics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dasatinib Generics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dasatinib Generics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dasatinib Generics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dasatinib Generics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dasatinib Generics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dasatinib Generics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dasatinib Generics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dasatinib Generics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dasatinib Generics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dasatinib Generics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dasatinib Generics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dasatinib Generics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dasatinib Generics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dasatinib Generics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dasatinib Generics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dasatinib Generics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dasatinib Generics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dasatinib Generics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dasatinib Generics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dasatinib Generics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dasatinib Generics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dasatinib Generics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dasatinib Generics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb Dasatinib Generics Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
  7. 8.2 Lupin
  8. 8.2.1 Lupin Company Information
  9. 8.2.2 Lupin Business Overview
  10. 8.2.3 Lupin Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Lupin Dasatinib Generics Product Portfolio
  12. 8.2.5 Lupin Recent Developments
  13. 8.3 Sawai Pharmaceutical
  14. 8.3.1 Sawai Pharmaceutical Company Information
  15. 8.3.2 Sawai Pharmaceutical Business Overview
  16. 8.3.3 Sawai Pharmaceutical Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sawai Pharmaceutical Dasatinib Generics Product Portfolio
  18. 8.3.5 Sawai Pharmaceutical Recent Developments
  19. 8.4 XSpray Pharma
  20. 8.4.1 XSpray Pharma Company Information
  21. 8.4.2 XSpray Pharma Business Overview
  22. 8.4.3 XSpray Pharma Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 XSpray Pharma Dasatinib Generics Product Portfolio
  24. 8.4.5 XSpray Pharma Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Dasatinib Generics Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 CSPC Ouyi Pharmaceutical
  32. 8.6.1 CSPC Ouyi Pharmaceutical Company Information
  33. 8.6.2 CSPC Ouyi Pharmaceutical Business Overview
  34. 8.6.3 CSPC Ouyi Pharmaceutical Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 CSPC Ouyi Pharmaceutical Dasatinib Generics Product Portfolio
  36. 8.6.5 CSPC Ouyi Pharmaceutical Recent Developments
  37. 8.7 Chia Tai Tianqing Pharmaceutical
  38. 8.7.1 Chia Tai Tianqing Pharmaceutical Company Information
  39. 8.7.2 Chia Tai Tianqing Pharmaceutical Business Overview
  40. 8.7.3 Chia Tai Tianqing Pharmaceutical Dasatinib Generics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Chia Tai Tianqing Pharmaceutical Dasatinib Generics Product Portfolio
  42. 8.7.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dasatinib Generics Value Chain Analysis
  2. 9.1.1 Dasatinib Generics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dasatinib Generics Sales Mode & Process
  6. 9.2 Dasatinib Generics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dasatinib Generics Distributors
  9. 9.2.3 Dasatinib Generics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst